SCHEMBL1600591

SCHEMBL1600591

Cc1ccc(-n2nc(C(C)(C)C)cc2C(=O)C(=O)O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRN P28799 2/20 0.62
SORT1 Q99523 2/20 0.62
CDK8 P49336 1/20 0.56
MAPK14 Q16539 7/20 0.53
MAPK13 O15264 4/20 0.53
MAPK12 P53778 4/20 0.53
MAPK11 Q15759 4/20 0.53
PTK2 Q05397 4/20 0.46
KDM4E B2RXH2 3/20 0.46
CYP2D6 P10635 2/20 0.46
CYP2C9 P11712 2/20 0.46
DDR2 Q16832 2/20 0.46
LMNA P02545 3/20 0.45
KMT2A Q03164 2/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ALDH1A1 P00352 1/20 0.45
MAPT P10636 1/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
CYP2C8 P10632 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12705325 0.90 GRN (0.78) GRNSORT1MAPK14MAPK13MAPK12
SCHEMBL1600233 0.88 GRN (0.80) GRNSORT1CDK8MAPK14MAPK13
SCHEMBL15948863 0.85 GRN (0.61) GRNSORT1CDK8MAPK14MAPK13
SCHEMBL1600158 0.85 CDK8 (0.55) GRNSORT1CDK8MAPK14MAPK13
SCHEMBL15946936 0.84 GRN (0.60) GRNSORT1CDK8MAPK14MAPK13
SCHEMBL1600416 0.84 CDK8 (0.64) GRNSORT1CDK8MAPK14MAPK13
SCHEMBL13263169 0.81 GRN (0.57) GRNSORT1CDK8MAPK14MAPK13
SCHEMBL19669089 0.81 GRN (0.57) GRNSORT1CDK8MAPK14MAPK13
SCHEMBL1517048 0.79 ALDH1A1 (0.59) GRNSORT1CDK8MAPK14MAPK13
SCHEMBL1600309 0.78 CDK8 (0.82) CDK8MAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670787-B1 CYTOKINE INHIBITORS ITHERX PHARMA INC (US) 2012-05-30 EP disclosed
US-7919617-B2 Cytokine inhibitors iTherX Pharmaceuticals Inc. (US) 2011-04-05 US disclosed
US-7897599-B2 Cytokine inhibitors iTherX Pharmaceuticals Inc. (US) 2011-03-01 US disclosed
US-20100273797-A1 ALPHA-KETOAMIDES AND DERIVATIVES THEREOF ITHERX PHARMACEUTICALS, INC. 2010-10-28 US disclosed
US-7749999-B2 Alpha-ketoamides and derivatives thereof ITHERX PHARMACEUTICALS, INC. (US) 2010-07-06 US disclosed
US-20100093734-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 US disclosed
US-20100093735-A1 CYTOKINE INHIBITORS ITHERX PHARMACEUTICALS, INC. (US) 2010-04-15 US disclosed
EP-1670787-A4 CYTOKINE INHIBITORS KEMIA INC (US) 2009-04-22 EP disclosed
EP-1670787-A2 CYTOKINE INHIBITORS Kemia, INC. (US) 2006-06-21 EP disclosed
US-20050107399-A1 Cytokine inhibitors KEMIA, INC. 2005-05-19 US disclosed
WO-2005023761-A2 CYTOKINE INHIBITORS KEMIA, INC. (US) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107399-A1 Cytokine inhibitors TNF, IL1RN, IL1A GRN 3147/4885SORT1 1605/4885CDK8 2319/4885
US-20100093734-A1 CYTOKINE INHIBITORS TNF, IL1RN, IL1A GRN 3147/4885SORT1 1605/4885CDK8 2319/4885
US-20100273797-A1 ALPHA-KETOAMIDES AND DERIVATIVES THEREOF TNF, IL1A, IL1B GRN 4668/4885SORT1 4163/4885CDK8 988/4885
US-20100093735-A1 CYTOKINE INHIBITORS TNF, IL1RN, IL1A GRN 3147/4885SORT1 1605/4885CDK8 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.